Nesvacumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nesvacumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Angiopoietin 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6440H9966N1722O2008S38
Molar mass 144.9 kg/mol

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1] As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.[2][3]

This drug is being developed by Regeneron Pharmaceuticals.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
  2. ^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov